Chronic inflammatory arthritis following checkpoint inhibitor therapy for cancer: game changing implications
Open Access
- 1 March 2020
- journal article
- editorial
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 79 (3) , 309-311
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessationAnnals of the Rheumatic Diseases, 2020
- Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy DrugsJAMA Network Open, 2019
- Association of HLA-DRB1 shared epitope alleles and immune checkpoint inhibitor-induced inflammatory arthritisRheumatology, 2018
- Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back againGenome Medicine, 2018
- Rheumatic immune-related adverse events from cancer immunotherapyNature Reviews Rheumatology, 2018
- The evolving role of the rheumatologist in the management of immune-related adverse events (irAEs) caused by cancer immunotherapyAnnals of the Rheumatic Diseases, 2018
- Measuring Toxic Effects and Time to Treatment Failure for Nivolumab Plus Ipilimumab in MelanomaJAMA Oncology, 2018
- Rheumatoid arthritis and polymyalgia rheumatica occurring after immune checkpoint inhibitor treatmentAnnals of the Rheumatic Diseases, 2017
- Rheumatic immune-related adverse events of checkpoint therapy for cancer: case series of a new nosological entityRMD Open, 2017
- Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumabAnnals of the Rheumatic Diseases, 2017